The effects of rontalizumab, an anti-IFN-α monoclonal antibody neutralizing all 12 IFN-α subtypes, in patients with moderate-to-severe SLE were evaluated in the ROSE trial. This evidence concerns the gene IFNA1 and systemic lupus erythematosus.